Dr. Ming-Wei Wang (Director, the National Center for Drug Screening/Chinese National Compound Library and Dean, School of Pharmacy, Fudan University) attended the 2019 Annual Board Meeting of Novo Nordisk Hemophilia Research Fund in China at Rujin Hospital affiliated to Shanghai Jiaotong University School of Medicine on April 25, 2019. Chaired by Chairman of the Board, Academician Sajuan Chen, the meeting discussed and approved the list of 2019 grant recipients and 2018 financial report. Chinese Board members who attended the meeting also include Drs. Xiaodong Xi (Shanghai Institute of Hematology), Yongqiang Zhao (Department of Hematology, Beijing Union Hospital), Renchi Yang (Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin), Professor Qiulan Ding (Fund Secretary; Department of Hematology, Ruijin Hospital) as well as Dr. Yinyin Chen of The National Center for Translational Medicine (Shanghai). Representing Novo Nordisk, Drs. Daniel B. Tiemmermann (Vice President), Carsten D. Ley (Director of Pharmacology), Jing Su (President of Novo Nordisk Research Centre China), Lu Dai (Senior Medical Affairs Manager) and Yongbing Chen (Medical Advisor) from Novo Nordisk (China) Pharmaceuticals Co., Ltd. were present.